This is a multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm,
parallel-group efficacy and safety study of NEOD001 as a single agent administered
intravenously in adults with AL amyloidosis who have a maintained hematologic response to
their most recent treatment for AL amyloidosis (e.g., chemotherapy, autologous stem cell
transplant [ASCT]) and have persistent renal dysfunction.